Regulatory Updates
Sep 16, 2026•1 min read
FDA Approves ANDA203048 for Clindamycin Phosphate Injection by Rising
The FDA granted approval for Rising’s clindamycin phosphate injection products (6, 12, and 18 mg/mL) under application ANDA203048.
Regulatory Updates
Sep 3, 2026•1 min read
FDA Approves ANDA209610 for Clindamycin Phosphate and Benzoyl Peroxide Gel
The FDA has approved ANDA209610 for a prescription topical gel combining clindamycin phosphate (EQ 1.2% base) and benzoyl peroxide (3.75%). The product is marketed by Padagis Israel Pharmaceuticals Ltd.
Regulatory Updates
Sep 2, 2026•1 min read
FDA Approves ANDA207047 for Clindamycin Palmitate Hydrochloride
The FDA has approved ANDA207047 for an oral clindamycin palmitate hydrochloride solution (75 mg/5 ml) marketed by Heritage Pharmaceuticals under sponsor APPCO.